hVIVO plc · LSE:HVO

hVIVO — Open Orphan — Investor Presentation (March 2022)

15 slides from hVIVO's investor presentation, March 2022

  1. Slide 1: Open Orphan plc

    Open Orphan plc March 2022

  2. Slide 2: Disclaimer

    Disclaimer • The contents of this presentation and the information which you are given at the time of the presentation have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation for the purpose of engagi

  3. Slide 3: Our Vision

    Our Vision World leader in testing infectious & respiratory disease products using human challenge studies addressing the growing infectious disease market 3

  4. Slide 4: Highlights

    Highlights  Subject to audit: • Expect full year EBITDA profitability FY21 • Expect c. £40m revenue for FY21 • Cash & cash equivalents 31 December 2021: £15.6m (30 June 2021: £14.9m) • Targeting c. £50m non-Covid revenue FY22 - Any COVID-19 revenue will be in addition to this  Bed capacity increas

  5. Slide 5: A Fast Growing Business

    A Fast Growing Business £46.6m 7 £75m Disclosed contract wins Challenge study Current Pipeline (Weighted) 2021 contract wins 2021 BD Pipeline X Probability of Award Expansion To facilitate growing pipeline & new service offering Plumbers Row office QMB: 24 + 7 beds New Manchester Facility + screenin

  6. Slide 6: Monetisation of Non-Core Assets

    Monetisation of Non-Core Assets • In June 2021, the first distribution in specie • FLU-v, Phase III ready universal flu vaccine was handed back to ORPH shareholders 49% • AGS-v, Phase II ready universal mosquito saliva • Created substantial value for Open Orphan stake vaccine shareholders • Still pu

  7. Slide 7: New CEO

    New CEO Yamin ‘Mo’ Khan appointed as CEO on 24 February • Cathal Friel will remain hands-on as Executive Chairman Biotech Experience • The Liposome Company Extensive CRO experience (25+ years) • Innovex – acquired by Quintiles • Pharm-Olam – acquired by PE - FTE expansion from 20 FTEs to 600+ FTEs -

  8. Slide 8: Open Orphan – at a Glance

    Open Orphan – at a Glance 1 Undisputed Leader in Challenge Studies 3 Human Challenge Trials Completed  30+ years providing world leading clinical  Deep roots dating back to 1947 with the Challenge # of # Patients trials service establishment of the UK Common Cold Clinic Model Trials Inoculated  6

  9. Slide 9: Open Orphan – at a Glance

    Open Orphan- at a Glance Open Orphan Location Overview of the Company’s Facilities hVIVO Location Name Description 1 Dublin Office Venn Location 2 Manchester 1 Dublin Office Flexible shared offices 3 Biobank 2 Manchester Recruitment & vaccination site 4 Plumbers Row 3 BioBank Storage unit for bioban

  10. Slide 10: Differentiated Volunteer / Patient recruitment

    Differentiated Volunteer / Patient recruitment  Central London and Manchester screening clinics provide a market 30 + leading advantage in recruiting Year History healthy subjects and patients for a broad range of trials amongst diverse  Decades of experience attracting suitable healthy subjects t

  11. Slide 11: Why Challenge Studies?

    Why Challenge Studies? • Potential for fast track / break through designation • Rapid approval or rejection of pre-clinical data • Phase II entry - up to 5x valuation uplift • Significant time / financial savings on efficacy data vs field-based Phase II • Facilitates dose ranging studies to support

  12. Slide 12: Potential Market

    Potential Market Strong Growth in Phase I and II Clinical Trial Starts(1,2) Increase in Phase I & I/II Infectious Disease & Respiratory Trials(3) 400 362 6.0 5.6 Coronavirus Dengue HRV Number of Trials in Thousands 4.9 350 TB RSV Malaria 5.0 4.5 4.7 1.2 303 4.0 4.0 4.3 300 Influenza Asthma 4.0 4.0 3

  13. Slide 13: Expanding our Capacity & Service Offering

    Expanding our Capacity & Service Offering Capacity & offering Challenge study models Laboratory facilities & services  New facilities in London & Manchester  STRiVE Project  New facilities  Supplemental recruitment services  Malaria  Increased biomarker & molecular  Non- first in human Phase

  14. Slide 14: Open Orphan – By the Numbers

    Open Orphan – By the Numbers Rapidly Growing c. £40M c. £50M £15.6M 2021P 2022P Cash at year end Specialist CRO Revenue Non-Covid Revenue 31 December 2021 Leader in Human 60 + 9+ £50M + Challenge Trials Completed Human Challenge Challenge Challenge Studies Study Models Model Portfolio Operational 84

  15. Slide 15: Questions

    Questions @OpenOrphan Open Orphan

Open Orphan — Investor Presentation (March 2022) on 6ix